tradingkey.logo

TherapeuticsMD Inc

TXMD
1.700USD
+0.030+1.80%
收盘 12/19, 16:00美东报价延迟15分钟
19.68M总市值
64.96市盈率 TTM

TherapeuticsMD Inc

1.700
+0.030+1.80%

关于 TherapeuticsMD Inc 公司

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

TherapeuticsMD Inc简介

公司代码TXMD
公司名称TherapeuticsMD Inc
上市日期Jan 31, 2001
CEOWalker (Marlan D)
员工数量1
证券类型Ordinary Share
年结日Jan 31
公司地址951 Yamato Road, Suite 220
城市BOCA RATON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编33431
电话15619611900
网址https://www.therapeuticsmd.com/
公司代码TXMD
上市日期Jan 31, 2001
CEOWalker (Marlan D)

TherapeuticsMD Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
--
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
--
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
7.50K
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
--
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
--
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
7.50K
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
Non-U.S
642.00K
67.44%
United States
310.00K
32.56%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Rubric Capital Management LP
10.30%
Clearline Capital LP
5.49%
The Vanguard Group, Inc.
3.26%
Tejara Capital Ltd.
2.97%
Adar1 Capital Management LLC
1.81%
其他
76.17%
持股股东
持股股东
占比
Rubric Capital Management LP
10.30%
Clearline Capital LP
5.49%
The Vanguard Group, Inc.
3.26%
Tejara Capital Ltd.
2.97%
Adar1 Capital Management LLC
1.81%
其他
76.17%
股东类型
持股股东
占比
Hedge Fund
18.44%
Investment Advisor
7.63%
Individual Investor
1.55%
Investment Advisor/Hedge Fund
1.39%
Research Firm
1.13%
其他
69.86%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
82
3.26M
28.17%
-348.35K
2025Q2
88
5.28M
45.63%
+1.46M
2025Q1
93
3.58M
30.94%
-393.28K
2024Q4
95
3.73M
32.32%
-2.03M
2024Q3
99
3.59M
31.15%
-463.34K
2024Q2
121
3.62M
31.37%
-2.25M
2024Q1
209
3.66M
32.13%
-802.21K
2023Q4
230
4.54M
44.12%
-1.60M
2023Q3
274
4.44M
43.31%
-158.22K
2023Q2
299
4.48M
44.55%
-545.84K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Rubric Capital Management LP
1.19M
10.3%
-1.75M
-59.54%
Jun 30, 2025
Clearline Capital LP
635.22K
5.49%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
379.00K
3.27%
-2.94K
-0.77%
Jun 30, 2025
Tejara Capital Ltd.
344.25K
2.97%
-341.00
-0.10%
Jun 30, 2025
Adar1 Capital Management LLC
209.21K
1.81%
-60.95K
-22.56%
Jun 30, 2025
Morgan Stanley & Co. LLC
130.12K
1.12%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
116.13K
1%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
109.08K
0.94%
-2.42K
-2.17%
Jun 30, 2025
Walker (Marlan D)
73.64K
0.64%
+2.79K
+3.94%
Apr 18, 2025
Collins (Cooper C)
60.52K
0.52%
--
--
Apr 18, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
公告日期
类型
比率
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1

常见问题

TherapeuticsMD Inc的前五大股东是谁?

TherapeuticsMD Inc 的前五大股东如下:
Rubric Capital Management LP持有股份:1.19M,占总股份比例:10.30%。
Clearline Capital LP持有股份:635.22K,占总股份比例:5.49%。
The Vanguard Group, Inc.持有股份:379.00K,占总股份比例:3.27%。
Tejara Capital Ltd.持有股份:344.25K,占总股份比例:2.97%。
Adar1 Capital Management LLC持有股份:209.21K,占总股份比例:1.81%。

TherapeuticsMD Inc的前三大股东类型是什么?

TherapeuticsMD Inc 的前三大股东类型分别是:
Rubric Capital Management LP
Clearline Capital LP
The Vanguard Group, Inc.

有多少机构持有TherapeuticsMD Inc(TXMD)的股份?

截至2025Q3,共有82家机构持有TherapeuticsMD Inc的股份,合计持有的股份价值约为3.26M,占公司总股份的28.17%。与2025Q2相比,机构持股有所增加,增幅为-17.46%。

哪个业务部门对TherapeuticsMD Inc的收入贡献最大?

在FY2025Q2,--业务部门对TherapeuticsMD Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI